Evidence map›Paper›PMID 30253446›Full record

ArticleInternational journal of urology : official journal of the Japanese Urological Association2018

Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.

Devin N Patel, Shalini Jha, Lauren E Howard, Christopher L Amling, William J Aronson, Matthew R Cooperberg, Christopher J Kane, Martha K Terris, Brian F Chapin, Stephen J Freedland

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of urology : official journal of the Japanese Urological Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 1 country.

Devin N PatelDivision of Urology, Department of Surgery, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Shalini JhaDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.
Lauren E HowardDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.
Christopher L AmlingDivision of Urology, Department of Urology, Oregon Health and Science University, Portland, Oregon, USA.
William J AronsonDepartment of Urology, Los Angeles School of Medicine, University of California, Los Angeles, California, USA.
Matthew R CooperbergDepartment of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.
Christopher J KaneUrology Department, University of California San Diego Health System, San Diego, California, USA.
Martha K TerrisSection of Urology, Veterans Affairs Medical Center, Augusta, Georgia, USA.
Brian F ChapinDepartment of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Stephen J FreedlandDivision of Urology, Department of Surgery, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Cedars-Sinai Medical Center · USDuke University · USAugusta University Health · USOregon Health & Science University · USThe University of Texas MD Anderson Cancer Center · USUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of California, Los Angeles · USUniversity of California, San Diego · US

Funding

Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate CancerR01CA231219 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARONSON, WILLIAM J, COHEN, PINCHAS · 2018 to 2022
$2.1M
Midcareer Investigator AwardK24CA160653 · NCI · DUKE UNIVERSITY · PI FREEDLAND, STEPHEN JAY · 2012 to 2016
$877k
NCI NIH HHS K24 CA160653NCI NIH HHS R01 CA231219
6 · The paper itself

Abstract

objectivesTo evaluate the impact of previous local treatment on survival in men with newly diagnosed metastatic castration-resistant prostate cancer.

methodsWe carried out a retrospective study of patients newly diagnosed with metastatic castration-resistant prostate cancer in the year 2000 or later from eight Veterans Affairs Medical Centers. Patients were categorized based on prior local therapy (none, prostatectomy ± radiation or radiation alone). Overall and cancer-specific survival was estimated by the Kaplan-Meier method. Cox proportional hazards regression models were used to test the association between prior local treatment and survival.

resultsOf 729 patients, 284 (39%) underwent no local treatment, 176 (24%) underwent radical prostatectomy ± radiation and 269 (37%) underwent radiation alone. On multivariable analysis, men with prior prostatectomy had improved overall (hazard ratio 0.71, P = 0.005) and cancer-specific survival (hazard ratio 0.55, P < 0.001) compared with men with no prior local therapy. This improvement in overall (hazard ratio 0.89, P = 0.219) and cancer-specific survival (hazard ratio 0.87, P = 0.170) was not seen in men with prior radiation alone. After further adjusting for comorbidity with the Charlson Comorbidity Index, patients with prior prostatectomy still had improved overall survival (hazard ratio 0.70, P = 0.003), whereas this was not seen in patients who received prior radiation alone (hazard ratio 0.88, P = 0.185).

conclusionsIndependent of patient- and disease-related factors, men with metastatic castration-resistant prostate cancer who had undergone prior radical prostatectomy have improved overall and cancer-specific survival compared with those with no prior local therapy.

Indexed as

AgedAged, 80 and overCancer Care FacilitiesFollow-Up StudiesHealth Services AccessibilityHospitals, VeteransHumansKaplan-Meier EstimateMaleNeoplasm Recurrence, LocalProstateProstatectomyProstatic Neoplasms, Castration-ResistantRadiotherapy, AdjuvantRegional Medical ProgramsRetrospective Studieslocal therapymetastatic castration-resistant prostate cancerradiation therapyradical prostatectomy

Identifiers

PMID30253446
PMCPMC6279517
OpenAlexW2892382636

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.